QTERN, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus: to improve glycaemic control when metformin and one of the monocomponents of QTERN do not provide adequate glycaemic control, when already being treated with the free combination of dapagliflozin and saxagliptin.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
